Modern treatments in CLL are thus designed to target the BCR pathway components of which some examples include: Bruton tyrosine kinase (BTK) inhibitor ibrutinib, and PI3K targeted by idelalisib (Hallek, 2019). Here, BCR is linked to B-cell chronic lymphocytic leukemia.